RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis

OBJECTIVES: Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) and modified RECIST (mRECIST) are commonly used to assess tumour response. Which one is better to evaluate efficacy after molecular targeted therapies in hepatocellular carcinoma (HCC) patients is still controversial....

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Hongli, Bai, Yuping, Xie, Xiaoyu, Feng, Yuemin, Yang, Yao, Zhu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161105/
https://www.ncbi.nlm.nih.gov/pubmed/35649603
http://dx.doi.org/10.1136/bmjopen-2021-052294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161105/
https://www.ncbi.nlm.nih.gov/pubmed/35649603
http://dx.doi.org/10.1136/bmjopen-2021-052294

Ejemplares similares